Expanding Pharmaceutical and Medical Businesses in the Life Innovation Field
First written in FY2016. 16 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「By increasing filtration performance to more than four times that of conventional products available from other companies, this product enables the module volume to be reduced to approximately one-fifth (Note). Benefits include space savings and reduced buffer solution requirements. Buffer solution is used to keep changes in pH, or acidity and alkalinity, constant.」
In the life innovation field, sales began for a high-efficiency separation membrane module for biopharmaceutical manufacturing, demonstrating concrete commercialization results of filtration performance more than four times higher and module volume approximately one-fifth that of conventional products. - FY2026-H1Declining revenue and widening lossAnnual report
「The Pharmaceuticals business recorded growth in overseas sales, led by China, but was affected in Japan by the increasing penetration of generic drugs. In the Medical Devices business, shipments of the core dialyzers for hemodiafiltration remained solid, but sales of catheters and other products remained sluggish. The business was also affected by persistently high raw material prices. As a result, overall Life Science segment revenue declined 2.0% year on year to ¥25.1 billion, while business profit declined by ¥500 million to a loss of ¥1.1 billion.」
Although pharmaceutical sales, mainly in China, and dialyzer shipments remained solid, the business loss widened due to sluggish sales of generic drugs, catheters, and other products, as well as persistently high raw material prices. - FY2025AdvancedAnnual report
「By reducing clogging in the manufacturing process for biopharmaceuticals, filtration performance has improved to more than twice that of conventional products, with expectations for higher yields and improved purification of biopharmaceuticals. The company is building a mass-production system with the aim of launching sales during fiscal 2025.」
In the Life Science business, the company developed a high-efficiency separation membrane module with filtration performance more than twice that of conventional products and is building a mass-production system for a sales launch during fiscal 2025. - FY2025-H1Higher revenue and continuing lossesAnnual report
「The Pharmaceuticals business was affected by the increasing penetration of generic drugs and drug price revisions, while overseas sales volumes remained sluggish. In the Medical Devices business, shipments of dialyzers for hemodiafiltration remained solid in Japan and overseas, but were affected by surging fuel and raw material prices. As a result, overall Life Science segment revenue increased 3.2% year on year to ¥25.6 billion, while business profit declined by ¥100 million to a loss of ¥600 million.」
In the life innovation field, solid dialyzer shipments led to higher revenue, but business profit remained in the red due to generic drugs, drug price revisions, sluggish overseas sales volumes, and surging fuel and raw material prices. - FY2024AdvancedAnnual report
「As a result, sales began for Toray APOA2-iTQ, an in vitro diagnostic product intended to aid the diagnosis of pancreatic cancer. The product is expected to enable early detection of pancreatic cancer patients who could not be detected using conventional tumor markers. In addition, Phase II clinical trials of TRK-950, which Toray is independently developing as a treatment for solid tumors, began in the United States, Japan, and South Korea for patients with gastric cancer.」
The company advanced to concrete development and commercialization milestones: the launch of a pancreatic cancer diagnostic product and the start of Phase II clinical trials of TRK-950 in three countries for patients with gastric cancer. - FY2024-Q3RestatedAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus, while the oral prostacyclin derivative formulation Dolner® was affected by inventory adjustments overseas. The Medical Devices business was affected by surging fuel and raw material prices, although domestic shipments of dialyzers for hemodiafiltration remained solid. As a result, overall Life Science segment revenue declined 4.5% year on year to ¥38.4 billion, while business profit declined by ¥1.4 billion to a loss of ¥800 million.」
As the impact of generic drugs, drug price revisions, overseas inventory adjustments, and surging fuel and raw material prices continued, the Life Science segment recorded lower revenue and remained in the red. - FY2024-Q2Lower revenue, with losses continuingAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus, while the oral prostacyclin derivative formulation Dolner® was affected by inventory adjustments overseas. The Medical Devices business was affected by surging fuel and raw material prices. As a result, overall Life Science segment revenue declined 4.3% year on year to ¥24.8 billion, while business profit declined by ¥900 million to a loss of ¥500 million.」
As the impact of generic drugs, drug price revisions, overseas inventory adjustments, and surging fuel and raw material prices continued, the Life Science segment recorded lower revenue and a business loss of ¥500 million. - FY2024-Q1Lower revenue and a shift into the redAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus, while the oral prostacyclin derivative formulation Dolner® was affected by inventory adjustments overseas. The Medical Devices business was affected by surging fuel and raw material prices. As a result, overall Life Science segment revenue declined 8.4% year on year to ¥11.3 billion, while business profit declined by ¥600 million to a loss of ¥500 million.」
The impact of generic drugs, drug price revisions, overseas inventory adjustments, and surging fuel and raw material prices resulted in lower revenue for the Life Science segment and a business loss of ¥500 million. - FY2023Revenue growth and a sharp profit declineAnnual report
「As a result, overall Life Science segment revenue increased 3.5% year on year to ¥53.8 billion, while business profit declined 86.2% to ¥200 million.」
Although overseas volumes of Dolner increased and dialyzers remained solid, profit declined sharply due to the impact of generic drugs, drug price revisions, and surging fuel and raw material prices. - FY2023-Q3Continued revenue growth and sharp profit declineAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus. In the Medical Devices business, domestic sales of dialyzers for hemodiafiltration remained solid, but were affected by surging fuel and raw material prices. As a result, overall Life Science segment revenue increased 4.2% year on year to ¥40.2 billion, while business profit declined 63.0% to ¥600 million.」
Although dialyzers remained solid and generated higher revenue, business profit declined 63.0% due to the impact of generic drugs, drug price revisions, and surging fuel and raw material prices. - FY2023-Q2Higher revenue and a widening decline in profitAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus. In the Medical Devices business, domestic sales of dialyzers for hemodiafiltration remained solid, but were affected by surging fuel and raw material prices. As a result, overall Life Science segment revenue increased 3.1% year on year to ¥25.9 billion, while business profit declined by ¥800 million to ¥300 million.」
Although medical devices remained solid, the Life Science segment recorded higher revenue while business profit declined by ¥800 million to ¥300 million due to the impact of generic drugs, drug price revisions, and surging fuel and raw material prices. - FY2023-Q1Higher revenue, slight decline in profitAnnual report
「As a result, overall Life Science segment revenue increased 7.6% year on year to ¥12.3 billion, while business profit declined by ¥100 million year on year to ¥100 million.」
Although the Life Science segment recorded higher revenue, business profit declined year on year due to the impact of generic drugs and drug price revisions on Remitch, as well as surging fuel and raw material prices affecting medical devices. - FY2022AdvancedAnnual report
「For TRK-950, a cancer treatment currently in Phase I clinical trials in cancer patients, new clinical trial sites have been added. Combination administration with existing anticancer drugs is being conducted across several cancer types to identify those for which high efficacy can be achieved.」
Development of TRK-950 is progressing through the addition of new clinical trial sites, combination administration with existing anticancer drugs across multiple cancer types, and narrowing down the target cancer types. - FY2022-Q3Slightly higher revenue; lower profitAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs and drug price revisions for Remitch® (Note 2), an oral treatment for pruritus. In the Medical Devices business, domestic demand for dialyzers for hemodiafiltration grew steadily, while demand for other medical devices also showed signs of recovery as COVID-19 infections temporarily subsided. As a result, overall Life Science segment revenue increased 0.5% year on year to ¥38.6 billion, while business profit declined 9.8% to ¥1.6 billion.」
Although demand for dialyzers and some medical devices recovered, the Life Science segment recorded a slight increase in revenue and lower profit due to the impact of generic drugs and drug price revisions. - FY2022-Q2AdvancedAnnual report
「As a result, overall Life Science segment revenue increased 1.7% year on year to ¥25.1 billion, while business profit increased 34.6% to ¥1.1 billion.」
The Life Science segment recorded higher revenue and higher profit due to increased overseas sales of Dolner and solid growth in domestic dialyzers. - FY2022-Q1Slight decline in revenue and modest increase in profitAnnual report
「As a result, overall Life Science segment revenue declined 0.8% year on year to ¥11.5 billion, while business profit increased by ¥100 million year on year to ¥200 million.」
Although Remitch was affected by generic drugs and drug price revisions, the Life Science segment's revenue declined only slightly, and business profit increased year on year. - FY2021AdvancedAnnual report
「For example, TRK-950, a new-concept antibody drug expected to be effective against many types of cancer, began Phase I clinical trials in the United States and France in March 2017. More than 100 patients have received the drug to date, with no safety issues identified. The company is continuing to confirm its safety and efficacy and aims to file an application promptly as a cancer treatment.」
TRK-950 has advanced to the stage of being administered to more than 100 patients in the United States and France, with safety and efficacy confirmation and an early application as the next objectives. - FY2021-Q3Lower Revenue; Higher ProfitAnnual report
「As a result, overall Life Science segment revenue declined 4.8% year on year to ¥38.4 billion, while business profit increased 9.3% to ¥1.8 billion.」
Although the impact of generic drugs, drug price revisions, and postponements of non-urgent surgeries remained, the Life Science segment recorded lower revenue while business profit increased 9.3% year on year. - FY2021-Q2Continued lower revenue and lower earningsAnnual report
「As a result, overall Life Science segment revenue declined 7.1% year on year to ¥24.7 billion, while business profit declined 22.9% to ¥800 million.」
The impact of generic drugs, drug price revisions, and postponements of non-urgent surgeries continued, resulting in lower revenue and lower profit for the Life Science segment. - FY2021-Q1Lower revenue and sharp earnings declinesAnnual report
「As a result, overall Life Science segment revenue declined 7.5% year on year to ¥11.6 billion, while business profit declined 87.5% to ¥100 million.」
The impact of generic versions of Remitch and drug price revisions, as well as the impact of postponements of non-urgent surgeries at medical institutions, was noted, resulting in lower revenue and a sharp decline in profit for the Life Science segment. - FY2020AdvancedAnnual report
「In addition, a pancreatic and biliary cancer test kit using the company's DNA chip, which is being developed for the early diagnosis of cancer, was designated in April 2019 by the Ministry of Health, Labour and Welfare as a product eligible for the SAKIGAKE designation for priority review of in vitro diagnostic products. The company aims to file an application during fiscal 2020.」
In the life innovation field, the pancreatic and biliary cancer test kit was designated as a product eligible for priority SAKIGAKE review, and a target was set for filing an application during fiscal 2020. The disclosure also mentions the expansion of U.S. clinical trial sites for TRK-950 and Toraymyxin's temporary use authorization in Canada. - FY2020-Q3Slight revenue decline, higher profitAnnual report
「As a result, overall Life Science segment revenue declined 0.5% year on year to ¥40.0 billion, while operating profit increased 51.2% to ¥1.9 billion.」
Although the Life Science segment recorded a slight decline in revenue, operating profit increased 51.2% year on year to ¥1.9 billion despite the impact of generic drugs. - FY2020-Q2AdvancedAnnual report
「The Pharmaceuticals business was affected by the launch of generic drugs for the oral prostacyclin derivative formulation Dolner®. Remitch®*, an oral treatment for pruritus, was also affected by the launch of generic drugs, but shipments remained solid, supported by growth in the overall market. The Medical Devices business recorded solid dialyzer shipments in Japan and overseas. As a result, overall Life Science segment revenue increased 1.1% year on year to ¥26.6 billion, while operating profit increased 93.6% to ¥1.3 billion.」
Despite the impact of generic drugs, shipments of Remitch and dialyzers remained solid, and operating profit in the Life Science segment increased 93.6%. - FY2020-Q1AdvancedAnnual report
「The Pharmaceuticals business increased the volume of the oral prostacyclin derivative formulation Dolner overseas, but was affected in Japan by generic drugs. Remitch, an oral treatment for pruritus, recorded a substantial volume increase from the previous year, when it had been affected by distribution inventory adjustments following the launch of generic drugs. The Medical Devices business recorded solid dialyzer shipments in Japan and overseas. As a result, overall Life Science segment revenue declined 1.8% year on year to ¥12.4 billion, while operating profit increased 283.7% to ¥600 million.」
Operating profit in the Life Science segment increased 283.7% year on year due to higher overseas volumes of Dolner, a recovery in Remitch volumes, and solid dialyzer shipments. - FY2019AdvancedAnnual report
「For TRK-250, the nucleic acid drug jointly developed with Bonac Co., Ltd., a Phase I clinical trial was launched in the United States. In addition, the drug was designated by the U.S. Food and Drug Administration as an orphan drug for idiopathic pulmonary fibrosis.」
The nucleic acid drug TRK-250 reached the stages of starting a Phase I clinical trial in the United States and receiving orphan drug designation. For TRK-950, the company is also adding clinical trial sites and exploring target cancer types through combination administration. - FY2019-Q3Continued slight revenue growth and profit declineAnnual report
「The Pharmaceuticals business increased the volume of the oral prostacyclin derivative formulation Dolner overseas, but was affected in Japan by generic drugs and drug price revisions. Remitch, an oral treatment for pruritus, was affected by the launch of generic drugs. In the Medical Devices business, dialyzers were affected by lower domestic reimbursement prices and higher raw material prices, but volumes grew steadily in Japan and overseas, while dialysis machines also increased in volume. As a result, overall Life Science segment revenue increased 1.1% year on year to ¥40.2 billion, while operating profit declined 36.2% to ¥1.2 billion.」
Although volumes of Dolner, dialyzers, and dialysis machines increased, revenue rose only slightly and operating profit continued to decline due to the impact of generic drugs, revisions to drug prices and reimbursement prices, and higher raw material prices. - FY2019-Q2Flat sales and lower profitAnnual report
「The Pharmaceuticals business increased the volume of the oral prostacyclin derivative formulation Dolner® overseas, but was affected in Japan by generic drugs and drug price revisions. Remitch®*, an oral treatment for pruritus, was affected by the launch of generic drugs. In the Medical Devices business, dialyzers were affected by lower domestic reimbursement prices and higher raw material prices, but volumes grew steadily in Japan and overseas, while dialysis machines also increased in volume. As a result, overall Life Science segment revenue increased 0.2% year on year to ¥26.3 billion, while operating profit declined 51.1% to ¥700 million.」
Although volumes of Dolner, dialyzers, and dialysis machines increased, revenue was essentially flat and operating profit declined sharply due to the impact of generic drugs, revisions to drug prices and reimbursement prices, and higher raw material prices. - FY2019-Q1Revenue growth and a sharp profit declineAnnual report
「In the Pharmaceutical business, overseas sales volumes of Dolner®, an oral prostacyclin derivative product, increased, but the product was affected in Japan by generic drugs and the drug price revision. Remitch®, an oral antipruritic drug, was affected by inventory adjustments ahead of the launch of a generic version. In the Medical Devices business, dialyzer shipments remained firm both in Japan and overseas, but were affected by lower domestic reimbursement prices and higher raw material costs. As a result, for the Life Science segment as a whole, revenue increased 3.6% year on year to ¥12.6 billion, while operating profit decreased 81.8% to ¥0.2 billion.」
Although overseas shipments of Dolner and dialyzers remained solid, profit declined sharply due to the impact of generic drugs, revisions to drug prices and reimbursement prices, distribution inventory adjustments, and higher raw material prices. - FY2018AdvancedAnnual report
「The company developed an orally disintegrating (OD) tablet of the antipruritic drug “TRK-820,” obtained domestic marketing approval for Remitch® (*1) OD tablets 2.5 μg, and began sales. It also continued Phase I clinical trials in the United States for “TRK-950,” a cancer treatment it is developing.」
Remitch OD tablets reached the milestones of obtaining domestic marketing approval and beginning sales, while TRK-950 continued in Phase I clinical trials in the United States. - FY2018-Q3AdvancedAnnual report
「In the Pharmaceutical business, shipments of Remitch®, an oral antipruritic agent, increased due to the launch of a new formulation and the additional indication. Meanwhile, shipments of Feron®, a natural interferon beta product, and Dolner®, an oral prostacyclin derivative product, remained sluggish due to the impact of alternative therapies and generic drugs. In the Medical Devices business, dialyzer shipments remained firm. As a result, for the Life Science segment as a whole, revenue increased 4.3% year on year to ¥39.8 billion, while operating profit increased 304.4% to ¥1.9 billion.」
Increased shipments of Remitch following the launch of a new formulation and the addition of indications, together with firm dialyzer shipments, resulted in revenue growth of 4.3% and operating profit growth of 304.4% for the Life Science business. - FY2018-Q2AdvancedAnnual report
「In the Pharmaceutical business, shipments of Remitch®, an oral antipruritic agent, increased, partly due to the effect of launching sales of the orally disintegrating (OD) tablet in June. Meanwhile, shipments of Feron®, a natural interferon beta product, and Dolner®, an oral prostacyclin derivative product, remained sluggish due to the impact of alternative therapies and generic drugs. In the Medical Devices business, dialyzer shipments remained firm both in Japan and overseas. As a result, for the Life Science segment as a whole, revenue increased 3.9% year on year to ¥26.2 billion, while operating profit increased 88.9% to ¥1.4 billion.」
Increased shipments following the launch of Remitch OD tablets and firm medical device shipments resulted in revenue growth of 3.9% and operating profit growth of 88.9% for the Life Science business. - FY2018-Q1AdvancedAnnual report
「In the Pharmaceutical business, shipments of Remitch®, an oral antipruritic agent, increased, partly due to the effect of launching sales of the orally disintegrating (OD) tablet in June. As a result, for the Life Science segment as a whole, revenue increased 2.9% year on year to ¥12.2 billion, while operating profit increased 275.4% to ¥0.8 billion.」
Sales of Remitch OD tablets began in June 2017, leading to increased shipments and a significant increase in operating profit for the Life Science business. - FY2017AdvancedAnnual report
「The company began a Phase I clinical trial in the United States for “TRK-950,” which it has been independently developing as a treatment for solid tumors. Going forward, it aims to pursue global clinical development in Europe and the United States and obtain early approval as a first-in-class cancer treatment.」
The new drug TRK-950 has reached the specific development milestone of entering a Phase I clinical trial in the United States. - FY2017-Q3RestatedAnnual report
「In the Pharmaceutical business, shipments of Remitch®, an oral antipruritic agent, increased against the backdrop of the additional indication approval obtained in 2015, but were affected by the April 2016 drug price revision. Shipments of Feron®, a natural interferon beta product, and Dolner®, an oral prostacyclin derivative product, remained sluggish due to the impact of alternative therapies and generic drugs. In the Medical Devices business, dialyzer shipments remained firm both in Japan and overseas.」
The company continued to report growth in Remitch sales volumes and firm medical device shipments, as well as downward pressure from the drug price revision, alternative therapies, and generic drugs. - FY2017-Q2RestatedAnnual report
「In the Pharmaceutical business, shipments of Remitch®, an oral antipruritic agent, increased against the backdrop of the additional indication approval obtained in 2015, but were affected by the April 2016 drug price revision. Shipments of Feron®, a natural interferon beta product, and Dolner®, an oral prostacyclin derivative product, remained sluggish due to the impact of alternative therapies and generic drugs. In the Medical Devices business, dialyzer shipments remained firm both in Japan and overseas.」
The company reported continued growth in Remitch sales volumes and firm medical device shipments, as well as downward pressure from the drug price revision, alternative therapies, and generic drugs. - FY2017-Q1AdvancedAnnual report
「In the Pharmaceutical business, sales volumes of Remitch®, an oral antipruritic agent, increased against the backdrop of the additional indication approval obtained in Japan in 2015 for use in chronic liver disease.」
The company reported that pharmaceutical sales volumes increased against the backdrop of the additional indication approval obtained in 2015. - FY2016First statedAnnual report
「As we strengthen our research and technological development capabilities with a view to expanding our business in the Life Innovation field, we are conducting drug discovery research in both synthetic and biologic pharmaceuticals. Using this introduction as a springboard, we will expand our efforts in nucleic acid pharmaceuticals and link them to further business growth.」
The company is advancing drug discovery research in both synthetic and biologic pharmaceuticals and plans to expand its efforts in nucleic acid pharmaceuticals.